{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:01:38Z","timestamp":1784894498958,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":194,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vigil Neuroscience, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (CSF1R-ALSP) is a rare, fatal, autosomal-dominant neurodegenerative disorder caused by pathogenic CSF1R variants and characterized by progressive cognitive, neuropsychiatric, and motor dysfunction, white matter lesions on brain imaging, and white matter demyelination, swollen axons, and pigmented glial cells on pathology. Limited data regarding clinical, biofluid or radiological biomarkers of disease severity are available, and no clinical trial endpoints have yet been validated. The objectives of this first-of-its-kind, prospective, observational natural history study were to characterize the clinical trajectory of CSF1R-ALSP and to identify and evaluate key biomarkers and clinical endpoints indicative of disease severity and progression. ILLUMINATE (NCT05020743) was a multicentre, noninterventional natural history study of adults with CSF1R-ALSP and prodromal carriers of CSF1R variants. Participants were followed for up to 36 months, with clinical assessments, fluid biomarkers and volumetric MRI assessments of brain atrophy collected at screening and every 6 months. This study was terminated early (4 June 2025). The analyses reported here include data collected through 19 February 2025. Of 53 participants, 19 were prodromal and 34 were symptomatic (11 of whom had a history of haematopoietic stem cell transplant and 23 who did not). Mean participant age was 47.8 (standard deviation, 4.5) years, and 36.4% were female. Prodromal participants remained relatively stable over 36 months, with little change in neurological function, neurodegeneration biomarkers or radiological disease burden. Impaired neurological function, MRI characteristics of CSF1R-ALSP, and elevated NfL (neurofilament light chain; neurodegeneration biomarker) and GFAP (glial fibrillary acidic protein; astrogliosis biomarker) levels were more pronounced at baseline and often showed progression over time among symptomatic participants who had not previously received haematopoietic stem cell transplant compared with participants who had previously received haematopoietic stem cell transplant. Significant correlations were observed at baseline and longitudinally between MRI measures of brain atrophy and clinical outcome measures. Based on the fluid biomarkers, MRI measures, and clinical outcome assessments evaluated here, active neurodegeneration, widespread changes visualized on brain MRI, and impaired cognitive and motor function were observed in symptomatic patients with CSF1R-ALSP. The neurological impairment can be assessed using the Montreal Cognitive Assessment and Cortical Basal ganglia Functional Scale. Our data suggest that quantification of brain atrophy using MRI volumetry is a potential biomarker of disease severity and progression in CSF1R-ALSP. It is hoped that this report will contribute to the understanding of disease progression in CSF1R-ALSP and inform future drug development.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag271","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:55:16Z","timestamp":1783770916000},"source":"Crossref","is-referenced-by-count":0,"title":["The ILLUMINATE natural history study in colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-7159","authenticated-orcid":false,"given":"David S","family":"Lynch","sequence":"first","affiliation":[{"name":"Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and NIHR University College London Hospitals Biomedical Research Centre , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Wade","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London , London WC1B 5EH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7774-5025","authenticated-orcid":false,"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases, T\u00fcbingen University Hospital , T\u00fcbingen 72076 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie N","family":"Hayer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases, T\u00fcbingen University Hospital , T\u00fcbingen 72076 ,","place":["Germany"]},{"name":"Institute of Human Genetics, University Medical Centre Hamburg-Eppendorf , Hamburg 20246 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M","family":"Gelfand","sequence":"additional","affiliation":[{"name":"UCSF Weill Institute for Neurosciences, University of California, San Francisco , San Francisco, CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-9545","authenticated-orcid":false,"given":"Wolfgang","family":"K\u00f6hler","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Leipzig Medical Centre , Leipzig 04103 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa-Caroline","family":"Bergner","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Leipzig Medical Centre , Leipzig 04103 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Victor Sgobbi","family":"de Souza","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, PSEG Centro de Pesquisa Cl\u00ednica , S\u00e3o Paulo, SP 04.038-002 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-7427","authenticated-orcid":false,"given":"Elizabeth C","family":"Finger","sequence":"additional","affiliation":[{"name":"Clinical Neurological Sciences, Western University , London, ON N6A 3K7 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-0728","authenticated-orcid":false,"given":"Nicole I","family":"Wolf","sequence":"additional","affiliation":[{"name":"Amsterdam Leukodystrophy Center, Department of Child Neurology, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam and Amsterdam Neuroscience , Amsterdam 1081 HV ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2945-6784","authenticated-orcid":false,"given":"Shanice","family":"Beerepoot","sequence":"additional","affiliation":[{"name":"Amsterdam Leukodystrophy Center, Department of Child Neurology, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam and Amsterdam Neuroscience , Amsterdam 1081 HV ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Orthmann-Murphy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania , Philadelphia, PA 19104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Chmiela","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic Florida , Jacksonville, FL 32224 ,","place":["USA"]},{"name":"Department of Neurology, Faculty of Medical Sciences, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Rajagovindan","sequence":"additional","affiliation":[{"name":"Formerly Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald G","family":"McLaren","sequence":"additional","affiliation":[{"name":"Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Gaudreault","sequence":"additional","affiliation":[{"name":"Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mirescu","sequence":"additional","affiliation":[{"name":"Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denitza","family":"Raitcheva","sequence":"additional","affiliation":[{"name":"Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meier","sequence":"additional","affiliation":[{"name":"Formerly Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gray","sequence":"additional","affiliation":[{"name":"Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chavez","sequence":"additional","affiliation":[{"name":"Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Vigil Neuroscience, Inc. , Watertown, MA 02472 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew K","family":"Wszolek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic Florida , Jacksonville, FL 32224 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026072407104293300_fcag271-B1","doi-asserted-by":"crossref","first-page":"788168","DOI":"10.3389\/fneur.2021.788168","article-title":"Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: Review of clinical manifestations as foundations for therapeutic development","volume":"12","author":"Papapetropoulos","year":"2022","journal-title":"Front Neurol"},{"issue":"2","key":"2026072407104293300_fcag271-B2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ng.1027","article-title":"Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids","volume":"44","author":"Rademakers","year":"2011","journal-title":"Nat Genet"},{"issue":"9","key":"2026072407104293300_fcag271-B3","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1007\/s00415-024-12557-0","article-title":"Novel variants in CSF1R associated with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)","volume":"271","author":"Schmitz","year":"2024","journal-title":"J Neurol"},{"issue":"4","key":"2026072407104293300_fcag271-B4","doi-asserted-by":"crossref","first-page":"e200179","DOI":"10.1212\/NXG.0000000000200179","article-title":"CSF1R-related disorder: Prevalence of CSF1R variants and their clinical significance in the UK population","volume":"10","author":"Wade","year":"2024","journal-title":"Neurol Genet"},{"issue":"24","key":"2026072407104293300_fcag271-B5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1212\/WNL.0000000000006642","article-title":"CSF1R-related leukoencephalopathy: A major player in primary microgliopathies","volume":"91","author":"Konno","year":"2018","journal-title":"Neurology"},{"key":"2026072407104293300_fcag271-B6","volume-title":"Genereviews\u00ae","author":"Dulski","year":"2012"},{"issue":"1","key":"2026072407104293300_fcag271-B7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ene.13125","article-title":"Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation","volume":"24","author":"Konno","year":"2017","journal-title":"Eur J Neurol"},{"key":"2026072407104293300_fcag271-B8","doi-asserted-by":"crossref","first-page":"1320663","DOI":"10.3389\/fneur.2024.1320663","article-title":"Clinical presentation and diagnosis of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): A literature analysis of case studies","volume":"15","author":"Papapetropoulos","year":"2024","journal-title":"Front Neurol"},{"issue":"5","key":"2026072407104293300_fcag271-B9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/17582024.2024.2404378","article-title":"Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: Developing a framework for improvements in care","volume":"14","author":"Rutherford","year":"2024","journal-title":"Neurodegener Dis Manag"},{"key":"2026072407104293300_fcag271-B10"},{"key":"2026072407104293300_fcag271-B11"},{"issue":"6","key":"2026072407104293300_fcag271-B12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/WNL.0b013e318263575a","article-title":"MRI characteristics and scoring in HDLS due to CSF1R gene mutations","volume":"79","author":"Sundal","year":"2012","journal-title":"Neurology"},{"issue":"12","key":"2026072407104293300_fcag271-B13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.wnl.0000325916.30701.21","article-title":"Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids","volume":"71","author":"Van Gerpen","year":"2008","journal-title":"Neurology"},{"issue":"17_supplement_2","key":"2026072407104293300_fcag271-B14","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1212\/WNL.0000000000203119","article-title":"Radiological features of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and its longitudinal progression (P8-4.003)","volume":"100","author":"Rajagovindan","year":"2023","journal-title":"Neurology"},{"key":"2026072407104293300_fcag271-B15","doi-asserted-by":"crossref","first-page":"123027","DOI":"10.1016\/j.jns.2024.123027","article-title":"Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): Estimation of pathological lesion stage from brain images","volume":"461","author":"Kinoshita","year":"2024","journal-title":"J Neurol Sci"},{"issue":"1-2","key":"2026072407104293300_fcag271-B16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jns.2011.10.006","article-title":"Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): A misdiagnosed disease entity","volume":"314","author":"Sundal","year":"2012","journal-title":"J Neurol Sci"},{"key":"2026072407104293300_fcag271-B17","author":"National Organization for Rare Disorders (NORD)"},{"issue":"Pt 6","key":"2026072407104293300_fcag271-B18","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/brain\/aww066","article-title":"CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids","volume":"139","author":"Eichler","year":"2016","journal-title":"Brain"},{"issue":"2","key":"2026072407104293300_fcag271-B19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/awz390","article-title":"Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia","volume":"143","author":"Gelfand","year":"2020","journal-title":"Brain"},{"issue":"12","key":"2026072407104293300_fcag271-B20","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/mds.28734","article-title":"Treatment of CSF1R-related leukoencephalopathy: Breaking new ground","volume":"36","author":"Tipton","year":"2021","journal-title":"Mov Disord"},{"issue":"12","key":"2026072407104293300_fcag271-B21","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/pharmaceutics14122778","article-title":"Hematopoietic stem cell transplantation in CSF1R-related leukoencephalopathy: Retrospective study on predictors of outcomes","volume":"14","author":"Dulski","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"2026072407104293300_fcag271-B22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/mds.30282","article-title":"Hematopoietic stem cell transplantation in an international cohort of colony stimulating factor-1 receptor (CSF1R)-related disorder","volume":"40","author":"Yska","year":"2025","journal-title":"Mov Disord"},{"issue":"12","key":"2026072407104293300_fcag271-B23","first-page":"1375","article-title":"Haematopoietic stem cell transplantation in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia","volume":"90","author":"Mochel","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2026072407104293300_fcag271-B24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s40478-020-01093-3","article-title":"Microglial replacement therapy: A potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy","volume":"8","author":"Han","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"6756","key":"2026072407104293300_fcag271-B25","doi-asserted-by":"crossref","DOI":"10.1126\/science.adr1015","article-title":"Microglia replacement halts the progression of microgliopathy in mice and humans","volume":"389","author":"Wu","year":"2025","journal-title":"Science"},{"key":"2026072407104293300_fcag271-B26","volume-title":"Statpearls","author":"Khaddour","year":"2023"},{"key":"2026072407104293300_fcag271-B27"},{"issue":"2","key":"2026072407104293300_fcag271-B28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/radiol.2019190306","article-title":"Atrophied brain T2 lesion volume at MRI is associated with disability progression and conversion to secondary progressive multiple sclerosis","volume":"293","author":"Genovese","year":"2019","journal-title":"Radiology"},{"issue":"Pt 9","key":"2026072407104293300_fcag271-B29","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/brain\/awn146","article-title":"Ventricular enlargement as a possible measure of Alzheimer\u2019s disease progression validated using the Alzheimer\u2019s disease neuroimaging initiative database","volume":"131","author":"Nestor","year":"2008","journal-title":"Brain"},{"key":"2026072407104293300_fcag271-B30"},{"issue":"4","key":"2026072407104293300_fcag271-B31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"2026072407104293300_fcag271-B32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/070674370705200508","article-title":"The Montreal cognitive assessment: Validity and utility in a memory clinic setting","volume":"52","author":"Smith","year":"2007","journal-title":"Can J Psychiatry"},{"issue":"1","key":"2026072407104293300_fcag271-B33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jalz.2019.05.013","article-title":"Use of the CDR\u00ae plus NACC FTLD in mild FTLD: Data from the ARTFL\/LEFFTDS consortium","volume":"16","author":"Miyagawa","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2026072407104293300_fcag271-B34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejpn.2018.10.001","article-title":"Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?","volume":"23","author":"Witherspoon","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"key":"2026072407104293300_fcag271-B35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/JMDH.S142520","article-title":"Timed up and go test combined with self-rated multifactorial questionnaire on falls risk and sociodemographic factors predicts falls among community-dwelling older adults better than the timed up and go test on its own","volume":"10","author":"Ibrahim","year":"2017","journal-title":"J Multidiscip Healthc"},{"issue":"3","key":"2026072407104293300_fcag271-B36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J Gerontol"},{"issue":"4","key":"2026072407104293300_fcag271-B37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1009530711710","article-title":"Factor structure of the burden interview","volume":"6","author":"Knight","year":"2000","journal-title":"J Clin Geropyschol"},{"key":"2026072407104293300_fcag271-B38","volume-title":"ECDEU Assessment manual for psychopharmacology","author":"Guy","year":"1976","edition":"Rev. ed."},{"key":"2026072407104293300_fcag271-B39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.parkreldis.2020.08.021","article-title":"The cortical basal ganglia functional scale (CBFS): Development and preliminary validation","volume":"79","author":"Lang","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"2026072407104293300_fcag271-B40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/acn3.70033","article-title":"Phase 1, first-in-human, single-\/multiple-ascending dose study of iluzanebart in healthy volunteers","volume":"12","author":"Meier","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"2026072407104293300_fcag271-B41","doi-asserted-by":"crossref","first-page":"e200187","DOI":"10.1212\/NXG.0000000000200187","article-title":"Global presence and penetrance of CSF1R-related disorder","volume":"10","author":"Dulski","year":"2024","journal-title":"Neurol Genet"},{"issue":"1","key":"2026072407104293300_fcag271-B42","doi-asserted-by":"crossref","first-page":"22128","DOI":"10.1038\/s41598-021-01499-6","article-title":"Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics","volume":"11","author":"Behzadi","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"2026072407104293300_fcag271-B43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol"},{"issue":"4","key":"2026072407104293300_fcag271-B44","doi-asserted-by":"crossref","first-page":"e0119681","DOI":"10.1371\/journal.pone.0119681","article-title":"Biomarkers of inflammation and axonal degeneration\/damage in patients with newly diagnosed multiple sclerosis: Contributions of the soluble CD163 CSF\/serum ratio to a biomarker panel","volume":"10","author":"Stilund","year":"2015","journal-title":"PLoS One"},{"issue":"458","key":"2026072407104293300_fcag271-B45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci Transl Med"},{"issue":"8","key":"2026072407104293300_fcag271-B46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/acn3.325","article-title":"Neurofilament light chain: A biomarker for genetic frontotemporal dementia","volume":"3","author":"Meeter","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2026072407104293300_fcag271-B47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","article-title":"Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system","volume":"32","author":"Hol","year":"2015","journal-title":"Curr Opin Cell Biol"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag271\/68795974\/fcag271.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/4\/fcag271\/68795974\/fcag271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/4\/fcag271\/68795974\/fcag271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:10:52Z","timestamp":1784891452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag271\/8734275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag271","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag271"}}